Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram

Levada, Oleg A.

doi:10.1016/j.jad.2019.03.040

Cited by 30 publications

(27 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Freeman et al (32) reported an improvement in DSST scores and in the Cognitive and Physical Functioning Questionnaire after treatment with a flexible dose of vortioxetine in the context of early postmenopausal and perimenopausal depression in 24 women (32). In an escitalopram-referenced trial, Levada and Troyan (62) specifically assessed the effects of vortioxetine on cognitive impairments and global, working, social, and family functioning in a cohort of 56 MDD patients. At week 8, both antidepressants exhibited procognitive effects.…”

Section: Methodsmentioning

confidence: 99%

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research

Bennabi

Haffen

Waes³

2019

Front. Psychiatry

View full text Add to dashboard Cite

Objectives: Vortioxetine has already shown its efficacy in the acute and long-term treatment of major depressive disorder (MDD) and its potential interest in the prevention of relapse. The aim of this study was to review the current status of knowledge regarding its cognitive effects. Methods: We conducted a review of key data obtained from preclinical behavioral models and clinical trials in MDD focusing on vortioxetine-induced cognitive changes. Results: In animals, acute and chronic administration of vortioxetine improves performance on objective measures that cover a broad range of cognitive domains. In human, vortioxetine appears to be a useful treatment option in MDD patients with cognitive dysfunction. Conclusion: Vortioxetine constitutes a promising treatment for treatment of cognitive impairment in MDD, but its place in the therapeutic armamentarium still needs to be determined.

show abstract

Section: Methodsmentioning

confidence: 99%

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research

Bennabi

Haffen

Waes³

2019

Front. Psychiatry

View full text Add to dashboard Cite

show abstract

“…Seventy-eight outpatients diagnosed with MDD according to DSM-5 criteria were recruited through Zaporizhzhia Regional Clinical Psychiatric Hospital, Ukraine. Eligibility criteria for the study inclusion were detailed elsewhere [15]. At study entry, all the patients received no actual antidepressant medication.…”

Section: Participants and Proceduresmentioning

confidence: 99%

Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study

Levada

Пінчук

2020

BMC Psychiatry

Self Cite

View full text Add to dashboard Cite

Background: IGF-1 is an essential neurotrophin produced peripherally and in the brain. Impairments in the brain IGF-1 concentrations might be responsible for some aspects of major depressive disorder (MDD) pathogenesis, whereas peripheral IGF-1 could have the marker value. We aimed: 1) to compare serum IGF-1 levels in MDD patients and healthy controls (HC); 2) to elucidate possible associations between changes in IGF-1 expression and crucial characteristics of the current depressive episode, MDD course; 3) to evaluate IGF-1 dynamics after 8 weeksv ortioxetine treatment. Methods: Seventy-eight MDD patients (according to DSM-5) and 47 HC were enrolled. Serum IGF-1, psychopathological (MADRS, CGI) and neuropsychological parameters (PDQ-5, RAVLT, TMT-B, DSST) were analyzed in all subjects at admission and 48 patients after 8 weeks`vortioxetine treatment. AUC-ROCs were calculated to determine if the value of serum IGF-1 could separate MDD patients from HC. Multiple regression models were performed to explore relationships between IGF-1 and depressive episode's symptoms. Results: MDD patients had significantly higher serum IGF-1 levels than HC (228 (183-312) ng/ml vs 153 (129-186) ng/ml, p < 0.0001). IGF-1 had a good diagnostic value for predicting MDD in the whole sample with AUC of 0.820 (p < 0.0001). For a cutoff of 178.00 ng/ml, the sensitivity and specificity were 83 and 71%, respectively, and the number needed to misdiagnose was 5, indicating that only 1 of 5 tests give an invalid result. Among MADRS items, only reported sadness, inner tension, and concentration difficulties were significantly positively associated with serum IGF-1 concentrations. Vortioxetine treatment significantly attenuated IGF-1 levels and improved all psychopathological, neuropsychological parameters.

show abstract

“…Outpatients (n=41) with MDD diagnosis according to DSM-5 criteria (28) were included through Zaporizhzhia Regional Clinical Psychiatric Hospital, Ukraine. Eligibility criteria for the study participants were described elsewhere (29). Before entering the study, all patients had received no actual antidepressant medication.…”

Section: Methodsmentioning

confidence: 99%

“…Before entering the study, all patients had received no actual antidepressant medication. Subjects were excluded if they had any other psychiatric diagnosis, high suicidal risk, substance dependence/abuse over the past year, significant neurological disorders, head trauma, unstable medical conditions, history of endocrine diseases, psychotic symptoms, the risk for the hypomanic switch (29). Thirty-two healthy controls (HC) with no current psychiatric disorder were enrolled within the same period that the MDD patients were included.…”

Section: Methodsmentioning

confidence: 99%

“…Thirty-two healthy controls (HC) with no current psychiatric disorder were enrolled within the same period that the MDD patients were included. HC were excluded based on the use of medications and/or illicit drugs; the intake of alcohol within 48 h of the study visit; and the presence of an unstable medical condition, which could affect cognitive function (29).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

The Diagnostic Value of the Combination of Serum Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 for Major Depressive Disorder Diagnosis and Treatment Efficacy

Troyan

2020

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

Background: Last decades of psychiatric investigations have been marked by a search for biological markers that can clarify etiology and pathogenesis, confirm the diagnosis, screen individuals at risk, define the severity, and predict the course of mental disorders. In our study, we aimed to evaluate if BDNF and IGF-1 serum concentrations separately and in combination might be used as biomarkers for major depressive disorder (MDD) diagnosis and treatment efficacy and to evaluate the relationships among those proteins and clinical parameters of MDD. Methods: Forty-one MDD patients (according to DSM-5) and 32 healthy controls (HC) were included in this study. BDNF and IGF-1 serum concentrations, psychopathological (MADRS, CGI) and neuropsychological parameters (PDQ-5, RAVLT, TMT-B, DSST), functioning according to Sheehan Disability Scale were analyzed in all subjects at admission and 30 MDD patients after 8 weeks of vortioxetine treatment. Correlational analyses were performed to explore relationships between BDNF and IGF-1 and clinical characteristics. AUC-ROCs were calculated to determine if the value of serum BDNF and IGF-1 levels could serve for MDD diagnosis. Results: MDD patients had significantly lower serum BDNF (727.6 ± 87.9 pg/ml vs. 853.0 ± 93.9 pg/ml) and higher serum IGF-1 levels (289.15 ± 125.3 ng/ml vs. 170.2 ± 58.2 ng/ ml) compared to HC. Significant correlations were obtained between BDNF levels and MDD status, depressive episode (DE) severity, precipitating factors, executive functions disruption (TMT-B, RAVLT immediate recall scores) and all subdomains of functioning. As for IGF-1, correlations were found between IGF-1 level and MDD status, DE severity, number and duration of DE, parameters of subjective and objective cognitive functioning (PDQ-5, RAVLT, TMT-B, DSST scores), and all subdomains of functioning. The associations between IGF-1 concentrations and cognitive tests' performance were stronger than those of BDNF. Separately both BDNF and IGF-1 demonstrated good

show abstract

Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram

Cited by 30 publications

References 50 publications

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research

Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research

Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study

The Diagnostic Value of the Combination of Serum Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 for Major Depressive Disorder Diagnosis and Treatment Efficacy

Contact Info

Product

Resources

About